Zosano Pharma Corporation announced the appointment of Linda Grais, M.D., J.D. to its board of directors. Dr. Grais brings a diverse and important set of experience and expertise to Zosano. She was an assistant professor at UCSF in internal medicine, received her J.D. from Stanford Law School where she was an editor of Stanford Law and Policy Review before joining Wilson Sonsini Goodrich & Rosati as an associate representing Life Science companies. Dr. Grais then founded Structural GenomiX Inc, which was sold to Eli Lilly & Co. in 2008 and became a partner at InterWest Partners, a venture capital firm, investing in biotechnology and medical device companies. Dr. Grais became the President and CEO of Ocera Therapeutics Inc. in 2012 and successfully led Ocera through the acquisition by Mallinckrodt in 2017. She currently serves on the Board of Directors of Arca Biopharma and PRA Health Sciences.